Halberd Corporation (HALB)
| Previous Close | 0.0078 |
| Open | 0.0083 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0075 - 0.0083 |
| 52 Week Range | 0.0030 - 0.0122 |
| Volume | |
| Avg. Volume | 936,771 |
| Market Cap | 1.824M |
| Beta (5Y Monthly) | -3.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREHalberd's Traumatic Brain Injury Treatment Projects Align with New U.S. House Bill
Daniel J. Harvey and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act, passed the U.S. House unanimously. JACKSON CENTER, PA / ACCESSWIRE / May 9, 2024 / Halberd Corporation's (OTC PINK:HALB) two active programs for the ...
- ACCESSWIRE
Halberd's Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans
LDN+ Drug Designed to Combat PTSD and Suicidal Ideation JACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation (OTC PINK:HALB) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited ...
- ACCESSWIRE
Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract
JACKSON CENTER, PA / ACCESSWIRE / April 4, 2024 / Halberd Corporation's (OTC PINK:HALB) Patented LDN+ Drug hits an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd ...
